NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
Clinical Trials
12 trialsNCT02978404 2024-06-28
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Completed
NCT03679767 2023-07-21
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
Phase 2 Completed
NCT02917772 2022-10-06
TITAN-RCC
AIO-Studien-gGmbH
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT02019576 2021-03-23
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT01499121 2018-03-06
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT01521715 2017-08-23
FLIPPER
iOMEDICO AG
Phase 4 Completed
NCT01715935 2016-08-19
NEORAD
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT02002312 2015-08-13
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Radboud University Medical Center
Phase 2 Completed